HK1123282A1 - Oxygen linked pyrimidine derivatives - Google Patents
Oxygen linked pyrimidine derivativesInfo
- Publication number
- HK1123282A1 HK1123282A1 HK09100412.1A HK09100412A HK1123282A1 HK 1123282 A1 HK1123282 A1 HK 1123282A1 HK 09100412 A HK09100412 A HK 09100412A HK 1123282 A1 HK1123282 A1 HK 1123282A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- oxygen linked
- pyrimidine derivatives
- linked pyrimidine
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73683805P | 2005-11-16 | 2005-11-16 | |
US81733906P | 2006-06-30 | 2006-06-30 | |
US85128306P | 2006-10-13 | 2006-10-13 | |
PCT/SG2006/000352 WO2007058627A1 (en) | 2005-11-16 | 2006-11-15 | Oxygen linked pyrimidine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1123282A1 true HK1123282A1 (en) | 2009-06-12 |
Family
ID=38048928
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09100412.1A HK1123282A1 (en) | 2005-11-16 | 2009-01-15 | Oxygen linked pyrimidine derivatives |
HK09100507.7A HK1124040A1 (en) | 2005-11-16 | 2009-01-19 | Heteroalkyl linked pyrimidine derivatives |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09100507.7A HK1124040A1 (en) | 2005-11-16 | 2009-01-19 | Heteroalkyl linked pyrimidine derivatives |
Country Status (20)
Country | Link |
---|---|
US (5) | US8153632B2 (pt) |
EP (1) | EP1951729B1 (pt) |
JP (2) | JP5225856B2 (pt) |
KR (5) | KR101576159B1 (pt) |
CN (2) | CN101365703B (pt) |
AT (1) | ATE469158T1 (pt) |
AU (2) | AU2006316072B2 (pt) |
BR (1) | BRPI0618552B8 (pt) |
CA (2) | CA2629455C (pt) |
CY (1) | CY1116156T1 (pt) |
DE (1) | DE602006014579D1 (pt) |
DK (2) | DK1951729T3 (pt) |
ES (2) | ES2506040T3 (pt) |
HK (2) | HK1123282A1 (pt) |
MY (1) | MY148072A (pt) |
NZ (1) | NZ568325A (pt) |
PL (1) | PL1951729T3 (pt) |
PT (2) | PT1951730E (pt) |
TW (3) | TWI407961B (pt) |
WO (2) | WO2007058627A1 (pt) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA013904B1 (ru) | 2003-12-18 | 2010-08-30 | Янссен Фармацевтика Н.В. | Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов |
NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
DK1951684T3 (en) | 2005-11-01 | 2016-10-24 | Targegen Inc | BIARYLMETAPYRIMIDIN kinase inhibitors |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US10517876B2 (en) * | 2005-11-16 | 2019-12-31 | Cti Biopharma Corp. | Oxygen linked pyrimidine derivatives |
AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
EP2044084B1 (en) | 2006-07-13 | 2016-02-17 | Janssen Pharmaceutica NV | Mtki quinazoline derivatives |
WO2008105526A1 (ja) | 2007-03-01 | 2008-09-04 | Chugai Seiyaku Kabushiki Kaisha | マクロ環状化合物 |
WO2008140419A2 (en) * | 2007-05-15 | 2008-11-20 | S*Bio Pte Ltd | Pyridyl substituted pyrimidine derivatives |
WO2008140420A2 (en) * | 2007-05-15 | 2008-11-20 | S*Bio Pte Ltd | Pyrimidine derivatives |
CN101801188A (zh) * | 2007-07-12 | 2010-08-11 | 特拉加拉医药品公司 | 治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物 |
JP5536647B2 (ja) | 2007-07-27 | 2014-07-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピロロピリミジン |
DK2283024T3 (da) * | 2008-03-10 | 2013-08-05 | Janssen Pharmaceutica Nv | 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer |
CA2722326A1 (en) | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
WO2010068181A1 (en) * | 2008-12-11 | 2010-06-17 | S*Bio Pte Ltd | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt |
ES2536276T3 (es) | 2008-12-11 | 2015-05-22 | Cti Biopharma Corp. | Sal maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno |
PT2454266E (pt) * | 2009-07-15 | 2013-10-10 | Cell Therapeutics Inc | Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)- 7,12,25-trioxa-19,21,24-triaza-tetraciclo- [18.3.1.1(2,5).1(14)18)]hexacosa- 1(24),2,4,9,14,16,18(26),20,22-nonaeno |
WO2011097525A1 (en) * | 2010-02-05 | 2011-08-11 | Tragara Pharmaceuticals, Inc. | Solid state forms of macrocyclic kinase inhibitors |
TW201206946A (en) * | 2010-07-15 | 2012-02-16 | Bristol Myers Squibb Co | Compounds for the reduction of beta-amyloid production |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
CN102127087B (zh) * | 2011-01-21 | 2012-07-04 | 江苏先声药物研究有限公司 | 喹唑啉衍生物 |
CN102757448B (zh) * | 2011-04-26 | 2016-04-06 | 中南大学 | 大环类激酶抑制剂化合物、制备方法及其作为药物的应用 |
HUE029728T2 (en) * | 2011-09-30 | 2017-03-28 | Ipsen Pharma Sas | Macrocyclic LRRK2 kinase inhibitors |
US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
CN102617599B (zh) * | 2012-04-10 | 2014-04-16 | 江苏先声药物研究有限公司 | 大环类化合物及其应用 |
EP2970213A4 (en) * | 2013-03-14 | 2016-09-07 | Concert Pharmaceuticals Inc | PACRITINIB DEUTÉRIÉ |
EP2994471B1 (en) * | 2013-05-06 | 2017-05-17 | Merck Patent GmbH | Macrocycles as kinase inhibitors |
MA39823A (fr) * | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
ES2921875T3 (es) | 2014-08-11 | 2022-09-01 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1 |
TW201618773A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Btk抑制劑、pi3k抑制劑、jak-2抑制劑、及/或cdk4/6抑制劑的治療組合物 |
FR3025199B1 (fr) * | 2014-09-02 | 2016-09-23 | Pf Medicament | Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques |
FR3025200B1 (fr) * | 2014-09-02 | 2016-09-23 | Pf Medicament | Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques |
ES2717510T3 (es) | 2014-09-17 | 2019-06-21 | Oncodesign Sa | Inhibidores macrocíclicos de cinasa LRRK2 |
CA3000633C (en) | 2014-10-14 | 2023-10-03 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
WO2016149031A1 (en) * | 2015-03-18 | 2016-09-22 | Newave Pharmaceutical Llc | Covalent inhibitors of cdk-7 |
CN105061467B (zh) * | 2015-08-28 | 2017-08-25 | 苏州立新制药有限公司 | 一种帕克替尼的制备方法 |
CN105017282B (zh) * | 2015-08-28 | 2017-11-07 | 苏州明锐医药科技有限公司 | 帕克替尼的制备方法 |
ES2864853T3 (es) * | 2015-09-28 | 2021-10-14 | Cti Biopharma Corp | Pacritinib para su uso en el tratamiento de rechazo de trasplante |
CN108368129B (zh) * | 2015-10-08 | 2021-08-17 | 拜耳医药股份有限公司 | 改性大环化合物 |
CN115969854A (zh) * | 2016-03-24 | 2023-04-18 | 科瑞华生物技术有限公司 | 用tg02治疗癌症 |
WO2017196261A1 (en) * | 2016-05-11 | 2017-11-16 | National University Of Singapore | Jak and hdac dual-inhibitor compounds |
SG11202001441WA (en) * | 2017-08-18 | 2020-03-30 | Tragara Pharmaceuticals Inc | Polymorphic form of tg02 |
WO2019079357A1 (en) * | 2017-10-17 | 2019-04-25 | Silverback Therapeutics, Inc. | TNIK MODULATORS, CONJUGATES AND USES THEREOF |
CN108864145B (zh) * | 2018-09-14 | 2021-03-30 | 兆科(广州)肿瘤药物有限公司 | 一种氧联嘧啶衍生物的纯化方法 |
CN111269245B (zh) * | 2018-12-04 | 2021-08-27 | 杭州百新生物医药科技有限公司 | 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途 |
WO2020125513A1 (zh) * | 2018-12-19 | 2020-06-25 | 凯复制药有限公司 | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 |
BR112021011894A2 (pt) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
WO2020219603A1 (en) * | 2019-04-22 | 2020-10-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Use of tg02 for treating gliomas in pediatric subjects |
WO2021091535A1 (en) | 2019-11-05 | 2021-05-14 | Constellation Pharmaceuticals, Inc. | Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor |
WO2020256739A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
WO2020257644A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
CN113583020B (zh) * | 2020-04-30 | 2022-04-22 | 百极弘烨(广东)医药科技有限公司 | 一种jak2抑制剂及应用 |
CN113735879B (zh) * | 2020-05-27 | 2022-05-17 | 百极弘烨(广东)医药科技有限公司 | 一种大环jak抑制剂及其应用 |
WO2022056092A1 (en) * | 2020-09-11 | 2022-03-17 | Cti Biopharma Corp. | Methods of treating viral infection |
CN115490705A (zh) * | 2021-06-18 | 2022-12-20 | 成都凡诺西生物医药科技有限公司 | N-大环酰胺类化合物、其制备方法及其作为药物的应用 |
CN113603708B (zh) * | 2021-07-27 | 2023-08-11 | 中国药科大学 | 一种具有大环骨架结构的cdk9抑制剂的制备及其应用 |
CN114409674B (zh) * | 2022-01-28 | 2023-07-25 | 山东大学 | 一种JAK抑制剂Pacritinib的合成方法 |
CN117447407A (zh) * | 2023-12-19 | 2024-01-26 | 潍坊医学院 | 一种JAK2抑制剂Pacritinib及其中间体的制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
US5811515A (en) | 1995-06-12 | 1998-09-22 | California Institute Of Technology | Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis |
US6306987B1 (en) | 1997-06-27 | 2001-10-23 | Ciba Specialty Chemicals Corporation | Ruthenium and osmium catalysts |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
DE10239042A1 (de) * | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
ATE552003T1 (de) * | 2002-10-29 | 2012-04-15 | Msd Kk | Chinoxalinderivate |
US7151096B2 (en) | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
US20050096324A1 (en) * | 2003-11-05 | 2005-05-05 | Zhi-Fu Tao | Macrocyclic kinase inhibitors |
US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
AU2004298784B2 (en) * | 2003-12-18 | 2011-06-09 | Janssen Pharmaceutica N.V | 3-cyano-quinoline derivatives with antiproliferative activity |
EA013904B1 (ru) * | 2003-12-18 | 2010-08-30 | Янссен Фармацевтика Н.В. | Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов |
MY169441A (en) * | 2004-12-08 | 2019-04-11 | Janssen Pharmaceutica Nv | 2,4, (4,6) pyrimidine derivatives |
US9047780B2 (en) * | 2012-11-16 | 2015-06-02 | Robert Bosch Gmbh | Collision mitigation systems and methods using driver attentiveness |
-
2006
- 2006-11-15 KR KR1020147024470A patent/KR101576159B1/ko active IP Right Grant
- 2006-11-15 PT PT06813133T patent/PT1951730E/pt unknown
- 2006-11-15 AU AU2006316072A patent/AU2006316072B2/en active Active
- 2006-11-15 US US12/093,867 patent/US8153632B2/en active Active
- 2006-11-15 CN CN2006800506549A patent/CN101365703B/zh active Active
- 2006-11-15 ES ES06813132.5T patent/ES2506040T3/es active Active
- 2006-11-15 KR KR1020087013543A patent/KR101499594B1/ko active IP Right Grant
- 2006-11-15 MY MYPI20081674 patent/MY148072A/en unknown
- 2006-11-15 DE DE602006014579T patent/DE602006014579D1/de active Active
- 2006-11-15 US US12/093,874 patent/US8143255B2/en active Active
- 2006-11-15 JP JP2008541128A patent/JP5225856B2/ja active Active
- 2006-11-15 PL PL06813132T patent/PL1951729T3/pl unknown
- 2006-11-15 CN CN2006800506765A patent/CN101360751B/zh active Active
- 2006-11-15 TW TW95142288A patent/TWI407961B/zh active
- 2006-11-15 AT AT06813133T patent/ATE469158T1/de active
- 2006-11-15 KR KR1020147003871A patent/KR101568801B1/ko active IP Right Grant
- 2006-11-15 DK DK06813132.5T patent/DK1951729T3/da active
- 2006-11-15 AU AU2006316071A patent/AU2006316071B2/en active Active
- 2006-11-15 CA CA2629455A patent/CA2629455C/en active Active
- 2006-11-15 KR KR20087013542A patent/KR20080090390A/ko not_active Application Discontinuation
- 2006-11-15 ES ES06813133T patent/ES2346791T3/es active Active
- 2006-11-15 WO PCT/SG2006/000352 patent/WO2007058627A1/en active Application Filing
- 2006-11-15 EP EP06813132.5A patent/EP1951729B1/en active Active
- 2006-11-15 BR BRPI0618552A patent/BRPI0618552B8/pt active IP Right Grant
- 2006-11-15 TW TW095142296A patent/TWI506029B/zh active
- 2006-11-15 JP JP2008541129A patent/JP5380073B2/ja active Active
- 2006-11-15 KR KR1020147003872A patent/KR101513492B1/ko active IP Right Grant
- 2006-11-15 WO PCT/SG2006/000353 patent/WO2007058628A1/en active Application Filing
- 2006-11-15 DK DK06813133.3T patent/DK1951730T3/da active
- 2006-11-15 PT PT68131325T patent/PT1951729E/pt unknown
- 2006-11-15 TW TW103101503A patent/TWI525096B/zh active
- 2006-11-15 NZ NZ568325A patent/NZ568325A/en unknown
- 2006-11-15 CA CA2629443A patent/CA2629443C/en active Active
-
2009
- 2009-01-15 HK HK09100412.1A patent/HK1123282A1/xx unknown
- 2009-01-19 HK HK09100507.7A patent/HK1124040A1/xx unknown
-
2012
- 2012-02-13 US US13/371,837 patent/US9133214B2/en active Active
- 2012-04-04 US US13/438,989 patent/US8415338B2/en active Active
-
2013
- 2013-02-20 US US13/771,546 patent/US9573964B2/en active Active
-
2014
- 2014-09-25 CY CY20141100782T patent/CY1116156T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1951729T3 (pl) | Pochodne pirymidyny połączone przez atom tlenu | |
HK1145832A1 (en) | Pyrimidine substituted purine derivatives | |
MX2011006959A (es) | Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina. | |
TW200724537A (en) | Pyrimidine derivatives for treatment of hyperproliferative disorders | |
MX2009010047A (es) | Compuestos quimicos. | |
MX2007009649A (es) | Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer. | |
MX2009010045A (es) | Compuestos quimicos. | |
WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
MY191349A (en) | New pharmaceutical compositions for the treatment of hyper-proliferative disorders | |
IL184872A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
IL185063A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
MX2009009537A (es) | Nanoparticula que comprende rapamicina y albumina como agente anticancer. | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
MY179527A (en) | Catecholamine derivatives useful for the treatment of parkinson's disease | |
TW200738659A (en) | Novel compounds | |
MX2010003269A (es) | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. | |
TW200745102A (en) | Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof | |
EP1812112A4 (en) | CHEMICAL COMPOUNDS | |
TW200738611A (en) | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | |
EP2124554A4 (en) | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | |
WO2008140420A3 (en) | Pyrimidine derivatives | |
PL1732902T3 (pl) | Pochodne nukleozydów i ich terapeutyczne zastosowanie | |
WO2008140419A3 (en) | Pyridyl substituted pyrimidine derivatives | |
WO2008140421A3 (en) | Heterocycloalkyl substituted pyrimidine derivatives | |
MY148355A (en) | Crystal form of epothilone b and use in pharmaceutical compositions |